Release Date: 16-Jul-2024
Leads Biolabs ventured into the groundbreaking territory with the development of LBL-034, a GPRC5DxCD3 bispecific antibody designed specifically for the treatment of multiple myeloma. The choice of G protein-coupled receptor, class C, group 5, member D (GPRC5D) in this innovative therapeutic approach stems from a meticulous understanding of their relevance in the context of multiple myeloma, which positions LBL-034 as a worthy player in the cancer therapeutics domain. Janssen’s Talvey is currently the only approved GPRC5D-targeted T cell engager on the market.
GPRC5D is a cell surface receptor that is highly expressed on malignant plasma cells, making it an ideal target for therapies aimed at multiple myeloma. CD3, a component of T cells on the other hand, serves as the mediator of immune response. By combining GPRC5D and CD3-targeting abilities in LBL-034, Leads strategically addresses the need for specificity and effectiveness in targeting cancer cells while leveraging the power of the immune system. LBL-034 was developed on the company’s proprietary T cell engager antibody technology platform, LeadsBody.
The mechanism of action in LBL-034 is by virtue of it being a bispecific antibody. It facilitates communication between immune cells and cancer cells by binding to GPRC5D on myeloma cells and CD3 on T cells. This dual interaction stimulates T lymphocytes, prompting them to detect and destroy GPRC5D-expressing malignant plasma cells. The accuracy with which this targeting is carried out reduces off-target effects and increases the overall efficiency of the immune system response against multiple myeloma.
Leads is currently studying the safety, tolerability, pharmacokinetics, and efficacy of LBL-034 in patients with relapsed/refractory multiple myeloma in an ongoing phase I/II clinical trial. This trial was initiated in October 2023 after gaining clinical trial approval from the NMPA and FDA in July 2023. This first-in-human, dose-escalation and expansion clinical study has enrolled patients with relapsed/refractory multiple myeloma who have failed prior therapies including but not limited to at least one proteasome inhibitor, one immunomodulator as well as other standard treatments. Though clinical trial results are yet to be revealed, in toxicology studies in preclinical animal models, LBL-034 showed good tolerance and acceptable safety profile as determined by pharmacology, pathology and biochemistry analysis.
The future of LBL-034 looks promising for the treatment of multiple myeloma. If the ongoing clinical trial yields positive results, this bispecific antibody could join Talvey as a transformative addition to the therapeutic landscape for patients with this challenging hematological malignancy.
For Clinical Trials Information Contact